chartexchange

Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026

GlobeNewswire Inc. | Nov 9, 2026 8:30 AM EST

MIAMI, FL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced Veru’s Chief Scientific Officer, Dr. Gary Barnette, will deliver a podium presentation at ObesityWeek 2026, taking place November 14-17, 2026, in Washington DC. Results will be presented from a post hoc analysis of physical function in patients ≥65 years with obesity receiving a GLP-1 RA from the positive Phase 2b QUALITY study.

Read original article